12/2
10:14 am
clym
Climb Bio, Inc. (NASDAQ: CLYM) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $10.00 price target on the stock.
Low
Report
Climb Bio, Inc. (NASDAQ: CLYM) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $10.00 price target on the stock.